Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.81 |
| ▸ | CA1 | P00915 | 1/20 | 0.81 |
| ▸ | CA2 | P00918 | 1/20 | 0.81 |
| ▸ | CA3 | P07451 | 1/20 | 0.81 |
| ▸ | CA4 | P22748 | 1/20 | 0.81 |
| ▸ | CA6 | P23280 | 1/20 | 0.81 |
| ▸ | CA5A | P35218 | 1/20 | 0.81 |
| ▸ | CA7 | P43166 | 1/20 | 0.81 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.81 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.81 |
| ▸ | CA9 | Q16790 | 1/20 | 0.81 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.81 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.81 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.81 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931211 | 1.00 | CA12 (0.81) | CA12CA1CA2CA3CA4 | |
| SCHEMBL15912621 | 0.90 | CA12 (0.67) | CA12CA1CA2CA3CA4 | |
| SCHEMBL2520926 | 0.90 | CA12 (0.67) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL35330 | 0.90 | CA12 (1.00) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL223961 | 0.90 | CA12 (1.00) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL225889 | 0.90 | CA12 (1.00) | CA12CA1CA2CA3CA4 | |
| SCHEMBL18080796 | 0.88 | CA12 (0.77) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL28184085 | 0.88 | CA12 (0.97) | CA12CA1CA2CA3CA4 | |
| SCHEMBL13583863 | 0.88 | CA12 (0.71) | CA12CA1CA2CA3CA4 | |
| SCHEMBL13583868 | 0.88 | CA12 (0.71) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519382-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LACOSAMIDE | UNICHEM LAB LTD (IN) | 2021-10-27 | — | — | EP | claimed |
| US-8957252-B2 | Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives | INDOCO REMEDIES LIMITED (IN) | 2015-02-17 | — | — | US | disclosed |
| EP-2598476-B1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LTD (IN) | 2014-07-02 | — | — | EP | disclosed |
| EP-2598476-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | Indoco Remedies Limited (IN) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2013-05-16 | — | — | US | disclosed |
| WO-2012014226-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | LPXN, CACNA1B, PMP22 | CA12 138/4885CA1 78/4885CA2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.